Proximo Medical Partners With Acarix to Commercialize the Acarix CADScor System in the United States

November 18, 2021—Proximo Medical, LLC, announced a partnership with Acarix, a Swedish medical device company that provides solutions for rapid artificial intelligence (AI) to rule out coronary artery disease (CAD).

Proximo Medical is a business acceleration solution that addresses medical device commercialization challenges among start-up and established medical device technologies looking to expand adoption in the United States.

According to Proximo Medical, the Acarix CADScor system uses AI and a smart sensor to rule out CAD in patients experiencing symptoms of suspected CAD. The noninvasive assessment provides results to health care professionals and patients in less than 10 minutes.

The CADScor system received FDA de novo clearance in 2020 and a CPT III code approval by the American Medical Association in October 2021. The technology has also received CE Mark approval, advised Proximo Medical.

“CAD is a major burden on the United States health care system, and the diagnostic pathways are costly and stressful for patients,” commented Proximo Medical Chief Executive Officer Gabe Szabo in the press release. “The CADScor system is an innovative, ultrasensitive device designed to support a safe, reliable, and affordable rule-out of significant CAD at early stages of the diagnostic pathway. Proximo is excited to bring this technology to select United States cities.”

Per Persson, Chief Executive Officer of Acarix, added, “By partnering with Proximo Medical, we rapidly initiate the commercialization of the CADScor system in the United States, immediately gaining market access and an experienced cardiovascular sales force with expertise in launching innovations in cardiovascular technology.”